摘要
目的探讨华蟾素胶囊、依托泊苷联合顺铂在老年非小细胞肺癌患者中的应用及对炎症因子、血清肿瘤标志物的影响。方法选取2017年6月至2018年12月上海市杨浦区中心医院收治的老年非小细胞肺癌患者74例,按随机数表法分为依托泊苷组和联合组,每组37例。依托泊苷组给予依托泊苷联合顺铂治疗,联合组在依托泊苷组治疗的基础上联合华蟾素胶囊治疗,21 d为一个周期,4周期治疗后对患者效果进行评估,比较两组患者的临床治疗效果、治疗前后的炎症因子、血清肿瘤标志物水平。结果联合组患者的近期治疗总有效率为59.46%,明显高于依托泊苷组的37.84%,差异有统计学意义(P<0.05);治疗4周期后,联合组和依托泊苷组患者炎症因子白细胞介素-2(IL-2)[(34.09±2.49)ng/L vs(53.55±3.61)ng/L]、白细胞介素-12(IL-12)[(26.39±4.69)ng/Lvs(35.73±5.71)ng/L]、干扰素-γ(IFN-γ)[(38.91±4.52)ng/L vs(46.34±5.81)ng/L]比较,联合组明显低于依托泊苷组,差异均具有统计学意义(P<0.05);治疗4周期后,联合组和依托泊苷组患者的肿瘤标志物癌胚抗原(CEA)[(12.10±1.09)μg/L vs(18.48±1.53)μg/L]、细胞角蛋白19片段21-1(CYFRA21-1)[(2.15±0.39)μg/L vs(4.12±0.41)μg/L]、肿瘤抗原125(CA125)[(21.49±2.39)U/mL vs(27.81±2.86)U/mL]、血管内皮生长因子(VEGF)[(101.21±7.46)ng/L vs(132.39±10.46)ng/L]比较,联合组明显低于依托泊苷组,差异均具有统计学意义(P<0.05)。结论华蟾素胶囊、依托泊苷联合顺铂用于老年非小细胞肺癌中能降低患者的炎症因子水平,改善血清肿瘤标志物水平,其近期疗效较好。
Objective To investigate the application of Huachansu capsule plus etoposide combined with cisplatin in elderly patients with non-small-cell lung cancer and its influence on inflammatory factors and serum tumor markers.Methods Seventy-four elderly patients with non-small-cell lung cancer,who admitted to Yangpu District Central Hospital of Shanghai City from June 2017 to December 2018,were selected and divided into the etoposide group and the combination group according to random number table method,with 37 patients in each group.Etoposide combined with cisplatin was given in the etoposide group,and the combination group was treated with Huachanxu capsule in addition to the etoposide group treatment,with 21 days as one course.The effect was evaluated after the treatment for 4 courses,and the clinical therapeutic effect,inflammatory factors and serum tumor marker levels before and after treatment were compared.Results The total effective rate in the combination group was 59.46%,which was significantly higher than 37.84%in the etoposide group(P<0.05).After 4 courses of treatment,the interleukin-2(IL-2),interleukin-12(IL-12),interferon(IFN)-γ in the combination group were(34.09±2.49)ng/L,(26.39±4.69)ng/L,(38.91±4.52)ng/L,respectively,which were significantly lower than corresponding(53.55±3.61)ng/L,(35.73±5.71)ng/L,(46.34±5.81)ng/L in the etoposide group(all P<0.05);after 4 courses of treatment,the carcinoembryonic antigen(CEA),Keratin 19 fragment 21-1(CYFRA21-1),cancer antigen 125(CA125),vascular endothelial growth factor(VEGF)in the combination group were(12.10±1.09)μg/L,(2.15±0.39)μg/L,(21.49±2.39)U/mL,(101.21±7.46)ng/L,respectively,which were significantly low-er than corresponding(18.48±1.53)μg/L,(4.12±0.41)μg/L,(27.81±2.86) U/mL,(132.39±10.46)ng/L in the etoposide group(all P<0.05).Conclusion Huachansu capsule plus etoposide combined with cisplatin can reduce the level of inflammatory factors and improve the serum tumor markers in elderly patients with non-small-cell lung cancer.
作者
吴丽明
金鹿
马继明
宋成福
WU Li-ming;JIN Lu;MA Ji-ming;SONG Cheng-fu(Department of Geriatrics,Antu Branch of Yangpu District Central Hospital of Shanghai City,Shanghai 200090,CHINA)
出处
《海南医学》
CAS
2020年第1期20-23,共4页
Hainan Medical Journal
关键词
华蟾素胶囊
依托泊苷
顺铂
老年非小细胞肺癌
近期疗效
炎症因子
血清肿瘤标志物
Huachansu capsule
Etoposide
Cisplatin
Elderly non-small-cell lung cancer
Short-term efficacy
Inflammatory factors
Serum tumor markers
